Why Acadia Pharmaceuticals Bears Were Right Before The Drop

Holding Acadia Pharmaceuticals from the start of the year would have meant a 24.8% loss, including dividends. If you had made that call on 1 January 2026, you would now be looking back at upbeat projections for double digit revenue growth, solid margins, and a higher future P/E multiple that once supported a fair value above the entry price. Which part of that original case failed to properly account for pricing risk, product concentration, and execution across the CNS pipeline?

This theme extends beyond Acadia Pharmaceuticals. See which of 34 healthcare AI stocks may still merit a closer look.

The Argument You Would Have Been Weighing Up On Acadia Pharmaceuticals

The shares cost US$26.71 at the start of the period, and anyone looking at Acadia Pharmaceuticals then had to pick between two very different stories about where the business might head next.

On the optimistic side, the bullish narrative saw a fair value of US$29.32, a notional price implied by assumptions such as revenue growth of 11.2% and profit margins near 21.0%, helped by expanding DAYBUE and NUPLAZID demand and a broader CNS pipeline.

The bearish narrative pointed to a fair value of US$15.83, an implied level that reflected concerns that Medicare price negotiations, patent cliffs for NUPLAZID and DAYBUE, and margin compression toward 4.4% could cap longer term earnings power.

What The Results Changed For Acadia Pharmaceuticals

The biggest new fact for Acadia Pharmaceuticals was that Q2 2026 revenue reached US$307.959m with net income of US$31.5m, up from US$264.566m and US$26.666m in Q2 2025. Net margin edged from 10.1% to 10.2%. That improvement supported the optimistic case on execution, yet the modest margin level kept the more cautious view on long term profitability alive. The evidence cut both ways.

The key lesson is about which bullish claim to stress test. If the thesis leans on future margin strength, track net margin in each filing and ask whether it is actually moving toward the margin embedded in the original fair value story.

What You Would Be Paying For In Acadia Pharmaceuticals Today

Acadia Pharmaceuticals now trades at US$19.78, after a share price that declined 24.8% from the start of the year. The selected Narrative sets a Fair Value above that level, built around execution on existing neurology products and a more focused view of the late stage pipeline.

This argument leans on DAYBUE and NUPLAZID supporting scale, while remlifanserin in dementia related psychosis becomes a meaningful contributor. For that higher figure to be reached, a buyer today would need to believe DAYBUE lifecycle expansion and remlifanserin development progress largely as currently outlined.

"Sustained demand for DAYBUE and NUPLAZID at Acadia Pharmaceuticals, reflected in Q2 2026 revenue of US$308 million with both brands contributing double digit volume growth, supports the view that a growing treated patient base can continue to lift revenue and spread fixed costs over a larger sales base."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Before The Next Story Makes Headlines

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 47% below our estimate - builds a larger Pacific banking footprint by integrating a newly acquired regional lender.
• Company 2 - 21% below our estimate - supplies cloud-based digital forensics tools as law enforcement shifts from device extractions to SaaS.
• Company 3 - 41% below our estimate - overhauls payments and digital channels to turn heavier tech spending into transaction and fee growth.

Three companies from the same screener. Open the full list of 28 companies trading below our estimate →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com